triple therapy + celecoxib

This combination chemoprevention regimen, investigated by the Hospital Authority, Hong Kong, is designed to reduce the risk of gastric cancer in individuals infected with *Helicobacter pylori*. The regimen consists of a standard one-week 'triple therapy' for *H. pylori* eradication—typically comprising a proton pump inhibitor (such as lansoprazole) and two antibiotics (such as amoxicillin and clarithromycin)—followed by long-term administration of the selective cyclooxygenase-2 (COX-2) inhibitor, celecoxib. The rationale behind this dual approach is to eliminate the bacterial infection, a primary driver of gastric carcinogenesis, while simultaneously inhibiting the COX-2 enzyme, which is often overexpressed in gastric cancer and its precursor lesions. By addressing both the infectious and inflammatory pathways, the therapy aims to reverse pre-cancerous changes in the stomach mucosa and prevent the development of gastric adenocarcinoma.

Other names

H. pylori eradication therapy + COX-2 inhibitorTriple therapy plus celecoxibTriple therapy-Hospital Authority, Hong Kong-gastric cancer